Methotrexate is technically a chemotherapy drug. It was designed in the 1940s as a cancer treatment, first approved by the FDA in 1953, and is officially classified as both an antineoplastic (anti-cancer) agent and an immunomodulatory agent. But if your doctor prescribed it for rheumatoid arthritis or psoriasis, the dose you’re taking is dramatically different from what cancer patients receive, and so is the experience of being on it.
Why It’s Classified as Chemotherapy
Methotrexate works by blocking a step in how cells use folate, a B vitamin essential for making DNA. Specifically, it interferes with an enzyme that cells need to copy their genetic material and divide. When cells can’t complete this process, they stall and eventually die. That’s exactly what you want to happen to cancer cells, and it’s why methotrexate was originally developed as an anti-cancer drug.
The FDA classifies methotrexate as a cytotoxic agent, meaning it kills cells. The CDC’s National Institute for Occupational Safety and Health lists it as a hazardous drug that healthcare workers must handle with protective precautions. By every formal definition, methotrexate is chemotherapy.
The Dose Changes Everything
The difference between methotrexate for arthritis and methotrexate for cancer isn’t the drug itself. It’s how much you take. For rheumatoid arthritis, the typical starting dose is 7.5 milligrams once a week, sometimes increased to 20 or 25 milligrams per week. For psoriasis, the range is similar: 10 to 25 milligrams weekly.
Cancer protocols operate on a completely different scale. A patient with osteosarcoma might receive 12,000 milligrams in a single intravenous infusion. Doses for non-Hodgkin lymphoma can reach 8,000 milligrams per square meter of body surface area. For acute lymphoblastic leukemia, the range spans from 10 to 5,000 milligrams per square meter. At doses above 500 milligrams per square meter, patients need a rescue medication (leucovorin) to protect healthy cells from being destroyed alongside cancer cells.
To put that in perspective, someone with rheumatoid arthritis might take 15 milligrams in a week. A cancer patient could receive hundreds or thousands of times that amount in a single session.
How It Works Differently at Low Doses
At high doses, methotrexate overwhelms cells’ ability to make DNA. It kills rapidly dividing cells, which is why it’s effective against cancer but also why high-dose treatment causes severe side effects like significant hair loss and dangerous drops in blood cell counts.
At the low doses used for autoimmune conditions, the drug appears to work through a different pathway. Rather than simply killing cells, low-dose methotrexate reduces the energy supply available to immune cells, particularly T cells. It lowers levels of key energy molecules in these cells, which slows their ability to multiply and mount the overactive immune response that drives conditions like rheumatoid arthritis and psoriasis. The result is immune suppression rather than the widespread cell destruction seen in cancer treatment.
Side Effects at Low Doses vs. High Doses
The side effect experience reflects this dose gap. About 30% of people taking low-dose methotrexate for autoimmune conditions report nausea or stomach upset, which is the most common complaint. Some people experience fatigue in the day or two after their weekly dose. Mild hair thinning can happen but is far less dramatic than the hair loss associated with cancer chemotherapy.
High-dose methotrexate for cancer is a different situation entirely. It requires hospitalization, IV administration over hours, aggressive hydration, and close monitoring of kidney function and blood counts. The rescue medication given afterward is specifically designed to stop methotrexate from continuing to kill healthy cells once the infusion is complete. The side effect profile includes severe mouth sores, significant immune suppression, and the kind of hair loss people typically associate with the word “chemotherapy.”
What This Means If You’re Taking It
If you’ve been prescribed methotrexate for an autoimmune condition and someone asks whether you’re on chemo, the honest answer is complicated. Pharmacologically, yes, you’re taking a chemotherapy drug. But your experience will bear almost no resemblance to what people picture when they hear that word. You’re taking a weekly pill or injection at a fraction of an oncology dose, and your doctor is using the drug’s immune-modulating properties rather than its ability to destroy tumors.
Some rheumatologists avoid calling low-dose methotrexate “chemotherapy” because the term can frighten patients into refusing a treatment that has decades of evidence supporting its safety and effectiveness for arthritis. Others feel patients deserve to know the drug’s full classification. Both perspectives have merit. What matters practically is understanding that the 15-milligram weekly tablet in your medicine cabinet and the 12,000-milligram IV infusion in an oncology ward are the same molecule doing very different things at very different scales.
Regular blood work is standard for anyone on methotrexate, regardless of dose. Your doctor will monitor liver function and blood cell counts to catch potential problems early. This is a precaution tied to the drug’s mechanism, not a sign that you’re undergoing cancer-level treatment.